Longitudinal survey study reveals better patient-centered outcomes when switching to ubrogepant compared to triptan.
This real-world study demonstrated people with migraine who switched from a triptan to ubrogepant reported better outcomes than those who switched to a different triptan.
No takes yet. Share an insight, caveat, or question.
Lipton et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: